185eP Exploring the role of aspirin in immunotherapy response for non-small cell lung cancer

Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, and many patients present with advanced disease requiring systemic chemotherapy.Treatment tolerance and outcomes may be influenced by coexisting respiratory comorbidities.Bronchiectasis (BE), a chronic airway disease characterized by persistent inflammation and recurrent infection, is increasingly recognized among lung cancer patients; however, its clinical impact during chemotherapy remains unclear. Methods:We conducted a retrospective cohort study of patients with stage III-IV lung cancer who received systemic chemotherapy.Patients were classified according to the presence or absence of radiologically confirmed non-cystic bronchiectasis on baseline chest computed tomography.Planned outcomes included chemotherapyassociated respiratory morbidity, including time to first respiratory infection-related hospitalization, intensive care unit admission due to pulmonary infection, chemotherapy delay or dose reduction attributable to infection, and overall survival (OS).In this preliminary analysis, OS was estimated using the Kaplan-Meier method and compared using the log-rank test.Results: A total of 228 patients were included, of whom 13 had bronchiectasis and 215 did not.The mean age was 67.9 years in the BE group and 67.4 years in the non-BE group, with no significant difference between groups.Sex distribution and body mass index were also comparable.During follow-up, one death occurred in the BE group and 60 deaths occurred in the non-BE group.Median OS was not reached in either group, and no statistically significant difference in OS was observed (log-rank p = 0.164). Conclusions:In this preliminary analysis of patients with advanced lung cancer receiving chemotherapy, bronchiectasis was not associated with a statistically significant difference in overall survival.Ongoing analyses focusing on chemotherapyassociated respiratory morbidity and treatment disruption may better define the clinical impact of bronchiectasis in this population.